1507P Revolutionizing clinical trials: Harnessing artificial intelligence for optimized phase III studies in pancreatic cancer
Year: 2024
Type: article
Abstract: Pancreatic cancer (PC) constitutes over 3% of new cancer diagnoses in Europe, yet accounts for 7% of cancer deaths, ranking as the fourth leading cause of cancer mortality. PC remains lethal in over 80% of patients, with a 5-year relative survival rate of 13%. Although new therapies are explored, interventional clinical trials for PC represent merely 5.13% of global cancer trials. Addressing this high unmet need necessitates probing questions to enhance patient access to novel therapies and ensure robust trial design and execution.
Source: Annals of Oncology
Authors: M-E.A. Bonneterre, B. Lekh, O. Gudmundsen
Language: English
Subfield: Oncology
Field: Medicine
Domain: Health Sciences
Open Access status: hybrid
Estimated APC paid: $4,600
OpenAlex ID: W4402560485